QUESTA è LA PARTE CHE CI INTERESSA:
Hair regeneration - ICX-TRC
ICX-TRC consists of a suspension of autologous dermal papilla (DP) cells. These
cells are able to stimulate the generation of new hairs when injected into the
scalp in close proximity to the epithelial cells which generate the hair. The
purpose of the ongoing Phase II study being conducted by Dr Bessam Farjo in
Manchester is to optimise the delivery of the DP cells.
In this study, hair counts are obtained by shaving and photographing a small
section of scalp, injecting it and then applying a specialised image analysis
system to provide a total hair count. Two sub-groups were each injected with
autologous DP cells using different delivery techniques. The first group
focussed on delivery of the hair inductive DP cells, and in the second group
resident hair producing (epithelial) cells were also stimulated at the time of
delivery.
Although it is too early to determine fully the differences between the
sub-groups, the preliminary data are encouraging. In the first sub-group 2
patients out of 5 showed substantial increases in hair count (21 & 55%) at 24
weeks. In the second sub-group (5 patients in total) injected more recently, all
patients showed substantial and visible increased hair counts at 6 and/or 12
weeks (13-105%). We believe this increased hair production is attributable to
the interaction between the injected DP cells and the stimulated resident hair
producing cells.
A further 8 subjects will be treated with variations in delivery technique. The
full data set on all subjects at 24 weeks will be available in the middle of
2008. This detailed analysis will form the basis of further Phase II or Phase
III trials as appropriate.
At the end of the trial photographic data will be analysed from a much larger
area of treated scalp on all subjects at 12 months. Currently 2 patients have
been lost to follow up.
Hair regeneration - ICX-TRC
ICX-TRC consists of a suspension of autologous dermal papilla (DP) cells. These
cells are able to stimulate the generation of new hairs when injected into the
scalp in close proximity to the epithelial cells which generate the hair. The
purpose of the ongoing Phase II study being conducted by Dr Bessam Farjo in
Manchester is to optimise the delivery of the DP cells.
In this study, hair counts are obtained by shaving and photographing a small
section of scalp, injecting it and then applying a specialised image analysis
system to provide a total hair count. Two sub-groups were each injected with
autologous DP cells using different delivery techniques. The first group
focussed on delivery of the hair inductive DP cells, and in the second group
resident hair producing (epithelial) cells were also stimulated at the time of
delivery.
Although it is too early to determine fully the differences between the
sub-groups, the preliminary data are encouraging. In the first sub-group 2
patients out of 5 showed substantial increases in hair count (21 & 55%) at 24
weeks. In the second sub-group (5 patients in total) injected more recently, all
patients showed substantial and visible increased hair counts at 6 and/or 12
weeks (13-105%). We believe this increased hair production is attributable to
the interaction between the injected DP cells and the stimulated resident hair
producing cells.
A further 8 subjects will be treated with variations in delivery technique. The
full data set on all subjects at 24 weeks will be available in the middle of
2008. This detailed analysis will form the basis of further Phase II or Phase
III trials as appropriate.
At the end of the trial photographic data will be analysed from a much larger
area of treated scalp on all subjects at 12 months. Currently 2 patients have
been lost to follow up.
]